The Stretta procedure for chronic gastroesophageal reflux disease has been performed 18,000 times, and new regulatory approvals have expanded the procedure to international markets, the manufacturer announced. The recent regulatory approvals for Stretta (Mederi Therapeutics) occurred in Mexico, India, South Africa, Australia, Argentine and South Korea, and product launches are currently underway, according to a press release.
No comments:
Post a Comment